These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22267604)

  • 1. RNAi screening of the kinome with cytarabine in leukemias.
    Tibes R; Bogenberger JM; Chaudhuri L; Hagelstrom RT; Chow D; Buechel ME; Gonzales IM; Demuth T; Slack J; Mesa RA; Braggio E; Yin HH; Arora S; Azorsa DO
    Blood; 2012 Mar; 119(12):2863-72. PubMed ID: 22267604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
    Porter CC; Kim J; Fosmire S; Gearheart CM; van Linden A; Baturin D; Zaberezhnyy V; Patel PR; Gao D; Tan AC; DeGregori J
    Leukemia; 2012 Jun; 26(6):1266-76. PubMed ID: 22289989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.
    Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC
    Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
    Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
    Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside.
    Andreeff M; Tafuri A; Hegewisch-Becker S
    Haematol Blood Transfus; 1990; 33():747-62. PubMed ID: 2323674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
    Chen L; Hu N; Wang C; Zhao H
    Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
    Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
    Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
    Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
    Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
    Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
    Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
    Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
    Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
    Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
    Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
    Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
    Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
    Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
    Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
    Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
    Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
    Nawrocki ST; Kelly KR; Smith PG; Keaton M; Carraway H; Sekeres MA; Maciejewski JP; Carew JS
    Clin Cancer Res; 2015 Jan; 21(2):439-47. PubMed ID: 25388161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia.
    Yin B; Kogan SC; Dickins RA; Lowe SW; Largaespada DA
    Exp Hematol; 2006 May; 34(5):631-41. PubMed ID: 16647569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.